Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Review of samples from 20 patients with Covid-19 found those with profound immunosuppression after hematopoietic stem-cell transplantation or on cellular therapies may shed viable SARS-CoV-2 for ≥2 months. Covid-19 isolation precautions may need to be revised for this group.

New England Journal of Medicine